Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis

Overview

Journal Cell Mol Neurobiol

Publisher Springer

Specialties Cell Biology
Molecular Biology
Neurology

Date 2006 Jun 15

PMID 16773445

Citations 377

Authors

Joseph T Coyle

Affiliations

Soon will be listed here.

Abstract

: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.

Citing Articles

Effects of transcranial direct current stimulation combined with retrieval practice on semantic memory in patients with schizophrenia.

Pan W, Li T, Ma X, Huo X BMC Psychiatry. 2025; 25(1):214.

PMID: 40055696 PMC: 11889829. DOI: 10.1186/s12888-025-06530-y.

Alteration of microRNA expression in lymphocytes in patients with first-episode schizophrenia.

Huang J, Wang X BMC Psychiatry. 2025; 25(1):210.

PMID: 40055650 PMC: 11887151. DOI: 10.1186/s12888-025-06659-w.

Investigating Connectivity Gradients in Schizophrenia: Integrating Functional, Structural, and Genetic Perspectives.

Xiang J, Ma C, Chen X, Cheng C Brain Sci. 2025; 15(2).

PMID: 40002512 PMC: 11853694. DOI: 10.3390/brainsci15020179.

Mapping hippocampal glutamate in healthy aging with glutamate-weighted CEST (GluCEST) imaging.

Pecsok M, Robinson H, Atkins A, Calkins M, Elliott M, Mordy A Front Aging Neurosci. 2025; 16:1535158.

PMID: 39926356 PMC: 11802501. DOI: 10.3389/fnagi.2024.1535158.

Impact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: an update.

Nayak U, Manikkath J, Arora D, Mudgal J Metab Brain Dis. 2025; 40(2):119.

PMID: 39907868 PMC: 11799129. DOI: 10.1007/s11011-025-01548-3.

References

Andersen J, Lindberg V, Myhrer T . Effects of scopolamine and D-cycloserine on non-spatial reference memory in rats. Behav Brain Res. 2002; 129(1-2):211-6. DOI: 10.1016/s0166-4328(01)00318-7. View

Lahti A, Weiler M, Tamara Michaelidis B, Parwani A, Tamminga C . Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001; 25(4):455-67. DOI: 10.1016/S0893-133X(01)00243-3. View

Braff D, Geyer M, Swerdlow N . Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001; 156(2-3):234-58. DOI: 10.1007/s002130100810. View

Kegeles L, Abi-Dargham A, Zea-Ponce Y, Mann J, van Heertum R, Cooper T . Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000; 48(7):627-40. DOI: 10.1016/s0006-3223(00)00976-8. View

Yurgelun-Todd D, Coyle J, Gruber S, Renshaw P, Silveri M, Amico E . Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005; 138(1):23-31. DOI: 10.1016/j.pscychresns.2004.11.006. View

Paulson L, Martin P, Persson A, Nilsson C, Ljung E, Westman-Brinkmalm A . Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J Neurosci Res. 2003; 71(4):526-33. DOI: 10.1002/jnr.10509. View

Lisman J, Grace A . The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron. 2005; 46(5):703-13. DOI: 10.1016/j.neuron.2005.05.002. View

Hashimoto A, Chiba S, Chiba Y . Effect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat. Eur J Pharmacol. 2004; 495(2-3):153-8. DOI: 10.1016/j.ejphar.2004.05.036. View

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

10.

Mitelman S, Shihabuddin L, Brickman A, Hazlett E, Buchsbaum M . MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes. Am J Psychiatry. 2003; 160(12):2154-68. DOI: 10.1176/appi.ajp.160.12.2154. View

11.

Meltzer H, McGurk S . The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999; 25(2):233-55. DOI: 10.1093/oxfordjournals.schbul.a033376. View

12.

Passani L, Vonsattel J, Coyle J . Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res. 1997; 772(1-2):9-22. DOI: 10.1016/s0006-8993(97)00784-1. View

13.

ITIL T, Keskiner A, Kiremitci N, Holden J . Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J. 1967; 12(2):209-12. DOI: 10.1177/070674376701200217. View

14.

Holzman P, KRINGLEN E, Matthysse S, Flanagan S, Lipton R, Cramer G . A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins. Arch Gen Psychiatry. 1988; 45(7):641-7. DOI: 10.1001/archpsyc.1988.01800310049006. View

15.

Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N . Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet. 2004; 13(21):2699-708. DOI: 10.1093/hmg/ddh280. View

16.

Llado J, Caldero J, Ribera J, Tarabal O, Oppenheim R, Esquerda J . Opposing effects of excitatory amino acids on chick embryo spinal cord motoneurons: excitotoxic degeneration or prevention of programmed cell death. J Neurosci. 1999; 19(24):10803-12. PMC: 6784960. View

17.

Kinney G, Sur C, Burno M, Mallorga P, Williams J, Figueroa D . The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci. 2003; 23(20):7586-91. PMC: 6740762. View

18.

Li Q, Clark S, Lewis D, Wilson W . NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity. J Neurosci. 2002; 22(8):3070-80. PMC: 6757533. DOI: 20026304. View

19.

Goff D, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld D . A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999; 56(1):21-7. DOI: 10.1001/archpsyc.56.1.21. View

20.

Gisabella B, Bolshakov V, Benes F . Regulation of synaptic plasticity in a schizophrenia model. Proc Natl Acad Sci U S A. 2005; 102(37):13301-6. PMC: 1201605. DOI: 10.1073/pnas.0506034102. View